CS
REPL icon

Candriam SCA’s Replimune Group REPL Stock Holding History

Candriam SCA’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Buy
+394,027
New +$3.01M 0.02% 457
2025
Q3 		– Sell
-171,527
Closed -$1.59M – 696
2025
Q2 		$1.59M Buy
+171,527
New +$1.5M 0.01% 532
2023
Q4 		– Sell
-612,193
Closed -$10.5M – 721
2023
Q3 		$10.5M Hold
612,193
– – 0.07% 227
2023
Q2 		$14.2M Sell
612,193
-50,729
-8% -$991K 0.1% 205
2023
Q1 		$10.8M Hold
662,922
– – 0.07% 250
2022
Q4 		$18M Buy
662,922
+53,350
+9% +$1.11M 0.12% 184
2022
Q3 		$10.5M Buy
609,572
+117,068
+24% +$2.23M 0.07% 259
2022
Q2 		$8.61M Hold
492,504
– – 0.07% 244
2022
Q1 		$8.36M Sell
492,504
-27,008
-5% -$510K 0.06% 279
2021
Q4 		$14.1M Sell
519,512
-2,629
-0.5% -$78.6K 0.09% 219
2021
Q3 		$15.5M Buy
522,141
+36,153
+7% +$1.17M 0.11% 209
2021
Q2 		$18.7M Buy
485,988
+323,828
+200% +$11.1M 0.13% 188
2021
Q1 		$5.94M Buy
162,160
+6
+0% +$225 0.05% 344
2020
Q4 		$6.19M Buy
+162,154
New +$6.76M 0.05% 353

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Candriam SCA's REPL Position: Q1 2026 in Review

Candriam SCA opened a new position in Replimune Group (REPL) in Q1 2026: 394,027 shares worth $3.01M. The stake represents 0.02% of the portfolio and ranks #457 among its holdings. This is a return to the name: Candriam SCA previously reported a position in REPL as recently as Q2 2025.

Candriam SCA first reported a position in REPL in Q4 2020 and has held it in 14 quarters since. The position peaked at $18.7M in Q2 2021. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.

  • Candriam SCA held 394,027 shares of Replimune Group worth $3.01M as of Q1 2026.
  • Replimune Group was a new Candriam SCA position in Q1 2026.
  • Replimune Group made up 0.02% of Candriam SCA's portfolio in Q1 2026, its #457 holding.
  • Candriam SCA first reported a position in Replimune Group in Q4 2020 and has held it in 14 quarters since.
  • Candriam SCA's Replimune Group position peaked at $18.7M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.